Brain Tumours

Studiendesign Why Vinblastine?

Author Division Olaf Witt SIOP LGG 201X

PAge74 1/25/2016 | a

• Single agent activity Bouffet et al., JCO 2012, Phase II, n=51, 5 year PFS 42% • Low neurotoxicity => OPG/Thalamic tumors • Anti-angiogenic activity at low doses Klement et al., JCI 2000; Vacca et al., Blood 2004 • Phase I Carbo+VBL Jakacki et al., 2011, Carbo +VBL at 400mg/m2/d + VBL 4mg/m2/d 1 PR=>CR, 6 OR (1PR), 11 SD, 3 PD (total 21) 7/9 OPG: improvement of vision